Celldex Therapeutics Inc (NASDAQ: CLDX) on Friday, plunged -8.51% from the previous trading day, before settling in for the closing price of $25.74. Within the past 52 weeks, CLDX’s price has moved between $24.43 and $53.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 30.09%. The company achieved an average annual earnings per share of 15.95%. With a float of $64.69 million, this company’s outstanding shares have now reached $66.34 million.
Let’s determine the extent of company efficiency that accounts for 160 employees. In terms of profitability, gross margin is 76.63%, operating margin of -1745.97%, and the pretax margin is -1544.48%.
Celldex Therapeutics Inc (CLDX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Celldex Therapeutics Inc is 3.32%, while institutional ownership is 107.45%. The most recent insider transaction that took place on Nov 11 ’24, was worth 308,430. In this transaction PRESIDENT & CEO of this company bought 11,500 shares at a rate of $26.82, taking the stock ownership to the 40,284 shares. Before that another transaction happened on Jun 14 ’24, when Company’s SVP AND CFO sold 17,172 for $35.42, making the entire transaction worth $608,315. This insider now owns 28,125 shares in total.
Celldex Therapeutics Inc (CLDX) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.59 earnings per share (EPS) for the period topping the consensus outlook (set at -0.67) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.79 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.95% per share during the next fiscal year.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Celldex Therapeutics Inc (CLDX) is currently performing well based on its current performance indicators. A quick ratio of 24.27 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 143.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.57, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -3.23 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Looking closely at Celldex Therapeutics Inc (NASDAQ: CLDX), its last 5-days average volume was 1.02 million, which is a jump from its year-to-date volume of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 33.76%. Additionally, its Average True Range was 1.71.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 0.26%, which indicates a significant decrease from 1.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.18% in the past 14 days, which was lower than the 60.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.89, while its 200-day Moving Average is $37.11. However, in the short run, Celldex Therapeutics Inc’s stock first resistance to watch stands at $25.13. Second resistance stands at $26.71. The third major resistance level sits at $27.53. If the price goes on to break the first support level at $22.73, it is likely to go to the next support level at $21.91. Now, if the price goes above the second support level, the third support stands at $20.33.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
Market capitalization of the company is 1.43 billion based on 66,344K outstanding shares. Right now, sales total 6,880 K and income totals -141,430 K. The company made 3,190 K in profit during its latest quarter, and -42,120 K in sales during its previous quarter.
